Tobam Sells 37,857 Shares of Pfizer Inc. $PFE

Tobam lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 56.7% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 28,898 shares of the biopharmaceutical company’s stock after selling 37,857 shares during the period. Tobam’s holdings in Pfizer were worth $700,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the first quarter worth approximately $27,000. Curio Wealth LLC raised its position in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the last quarter. Bayforest Capital Ltd bought a new position in Pfizer in the 1st quarter worth approximately $28,000. Harbor Asset Planning Inc. acquired a new position in Pfizer during the 2nd quarter worth $29,000. Finally, WPG Advisers LLC bought a new position in Pfizer in the 1st quarter valued at $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 4.5%

Shares of NYSE PFE opened at $25.49 on Wednesday. The stock has a market capitalization of $144.93 billion, a P/E ratio of 13.56, a PEG ratio of 0.81 and a beta of 0.54. The stock’s fifty day moving average is $24.75 and its 200 day moving average is $24.41. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer’s dividend payout ratio is presently 100.00%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a report on Wednesday, November 5th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Morgan Stanley reduced their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. UBS Group reaffirmed a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Bank of America raised their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $28.18.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.